New Outdoor research sites in Quebec and British
Columbia to study best-in-class cultivation techniques and
advance plant science
NYSE: ACB TSX:ACB
EDMONTON, July 15, 2019 /PRNewswire/ - Aurora Cannabis Inc.
("Aurora" or the "Company") (NYSE: ACB) (TSX: ACB), the Canadian
company defining the future of cannabis worldwide, today announced
that it has received Health Canada licenses for outdoor cultivation
at two Canadian sites.
The new sites in Quebec and
British Columbia will be used for
cultivation research to develop new technology, genetics and
intellectual property in order to drive sustainable, high-quality
outdoor production. Aurora purposefully chose the outdoor sites
because they represent two different growing environments. The
company will conduct research on cultivation techniques to further
excel at growing cannabis in varying climate conditions and will
examine approaches to environmentally sustainable cannabis
agriculture.
The newly-named Western facility will be called Aurora Valley and is a 207-acre operation in
Westwold, British Columbia. The
Eastern facility, a 21,000 square foot operation at the Aurora Eau
facility in Lachute, is the first
approved outdoor grow operation for cannabis in Quebec. Aurora
Valley is expected to be planted shortly and Aurora Eau has
already been planted.
The two sites are an extension of the scientific research Aurora
will be conducting at its new Comox facility, which will be ready in the
fall of 2019. The Comox facility
consists of a 21,000 square foot indoor grow facility and a 10,500
square foot laboratory. This unique research centre will be home
for Aurora's plant breeding team designed to create new cannabis
cultivars with improved growing characteristics for both indoor and
outdoor cultivation.
"Aurora believes in innovative operations and intensive research
and we're applying our approach to outdoor grown cannabis," said
Aurora CEO Terry Booth. "Our team
plans to use these areas to ensure we are able to consistently grow
the high-quality cannabis Aurora has become known for around the
world. We're proud to be a Canadian company and this is a further
commitment to research and job creation in Canada."
Dr. Jonathan Page, Chief Science
Officer at Aurora added, "For this season and next, our focus will
be on researching cultivation methods and evaluating genetics in
order to produce high THC and CBD cannabis in outdoor-grown plants,
with the ultimate goal of extracting these components. The unique
climates of each site also presents a great opportunity to
determine which cultivars will perform best in different outdoor
environments."
In addition to the two new outdoor production sites, Aurora
confirms it has now received the Health Canada processing license
for its Aurora Air facility located near the Edmonton International Airport and Aurora Sky.
Aurora Air will be home to several of the new production lines for
edible products such as gummies and chocolates, to be introduced to
the Canadian consumer market in December
2019.
About Aurora
Headquartered in Edmonton, Alberta,
Canada with funded capacity in excess of 625,000 kg per
annum and sales and operations in 25 countries across five
continents, Aurora is one of the world's largest and leading
cannabis companies. Aurora is vertically integrated and
horizontally diversified across every key segment of the value
chain, from facility engineering and design to cannabis breeding
and genetics research, cannabis and hemp production, derivatives,
high value-add product development, home cultivation, wholesale and
retail distribution.
Highly differentiated from its peers, Aurora has established a
uniquely advanced, consistent and efficient production strategy,
based on purpose-built facilities that integrate leading-edge
technologies across all processes, defined by extensive automation
and customization, resulting in the massive scale production of
high-quality consistent product. Intended to be replicable and
scalable globally, our production facilities are designed to
produce cannabis of significant scale, with high quality,
industry-leading yields, and low per gram production costs. Each of
Aurora's facilities is built to meet European Union Good
Manufacturing Practices ("EU GMP") standards. Certification has
been granted to Aurora's first production facility in Mountain View
County, the MedReleaf Markham facility, and its wholly owned
European medical cannabis distributor Aurora Deutschland. All
Aurora facilities are designed and built to the EU GMP
standard.
In addition to the Company's rapid organic growth and strong
execution on strategic M&A, which to date includes 17 wholly
owned subsidiary companies – MedReleaf, CanvasRX, Peloton
Pharmaceutical, Aurora Deutschland, H2 Biopharma, Urban Cultivator,
BC Northern Lights, Larssen Greenhouses, CanniMed Therapeutics,
Anandia, HotHouse Consulting, MED Colombia, Agropro, Borela, ICC
Labs, Whistler, and Chemi Pharmaceutical – Aurora is distinguished
by its reputation as a partner and employer of choice in the global
cannabis sector, having invested in and established strategic
partnerships with a range of leading innovators, including: Radient
Technologies Inc. (TSXV: RTI), Hempco Food and Fiber Inc. (TSXV:
HEMP), Cann Group Ltd. (ASX: CAN), Micron Waste Technologies Inc.
(CSE: MWM), Choom Holdings Inc. (CSE: CHOO), CTT Pharmaceuticals
(OTCC: CTTH), Alcanna Inc. (TSX: CLIQ), High Tide Inc. (CSE: HITI),
EnWave Corporation (TSXV: ENW), Capcium Inc. (private), Evio Beauty
Group (private), and Wagner Dimas (private).
Aurora's Common Shares trade on the TSX and NYSE under the
symbol "ACB", and are a constituent of the S&P/TSX Composite
Index.
For more information about Aurora, please visit our investor
website, investor.auroramj.com
Terry Booth, CEO
Aurora Cannabis Inc.
Forward looking statements
This news release includes statements containing certain
"forward-looking information" within the meaning of applicable
securities law ("forward-looking statements"). Forward-looking
statements are frequently characterized by words such as "plan",
"continue", "expect", "project", "intend", "believe", "anticipate",
"estimate", "may", "will", "potential", "proposed" and other
similar words, or statements that certain events or conditions
"may" or "will" occur and are subject to inherent risks which
include, but are not limited to, the implementation of definitive
regulation of edible products and the Company's launch of edible
products in Canada, the successful
development and operation of the Company's newly licensed outdoor
facilities, the completion of the Air facility, and the
overall market demand for the Companies intended product offerings.
The Forward-looking statements are only predictions. Various
assumptions were used in drawing the conclusions or making the
projections contained in the forward-looking statements throughout
this news release. Forward-looking statements are based on the
opinions and estimates of management at the date the statements are
made, and are subject to a variety of risks and uncertainties and
other factors that could cause actual events or results to differ
materially from those projected in the forward-looking statements.
The Company is under no obligation, and expressly disclaims any
intention or obligation, to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise, except as expressly required by applicable law.
Neither TSX, NYSE nor their applicable Regulation Services
Providers (as that term is defined in the policies of the Toronto
Stock Exchange and New York Stock Exchange) accept responsibility
for the adequacy or accuracy of this release.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/aurora-cannabis-obtains-two-licences-for-outdoor-growing-operations-300884617.html
SOURCE Aurora Cannabis Inc.